Fingerprint
Dive into the research topics of 'Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial
Roger Li, Paras H. Shah, Tyler F. Stewart, Jong Kil Nam, Trinity J. Bivalacqua, Donald L. Lamm, Edward M. Uchio, Daniel M. Geynisman, Joseph M. Jacob, Joshua J. Meeks, Rian Dickstein, Shane M. Pearce, Seok Ho Kang, Seung Il Jung, Ashish M. Kamat, James M. Burke, Kirk A. Keegan, Gary D. Steinberg
- University of South Florida
- Mayo Clinic
- University of California at San Diego
- Pusan National University
- University of Pennsylvania
- BCG Oncology
- University of California at Irvine
- Upstate
- Northwestern University
- Chesapeake Urology
- Spokane Urology
- Korea University
- Chonnam National University
- University of Texas MD Anderson Cancer Center
- Billings Clinic
- CG Oncology
- Vanderbilt University
- Rush University
Research output: Contribution to journal › Article › peer-review
24
Scopus
citations